Computational models for prediction of interactions with ABC-transporters

Drug Discovery Today

Volumn 13, Issue 7-8, 2008, Pages 311-317

  Ecker, Gerhard F ^a   Stockner, Thomas ^b   Chiba, Peter ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b ARC SEIBERSDORF RESEARCH GMBH   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; GLYCOPROTEIN P; NUCLEOTIDE BINDING PROTEIN;

ALGORITHM; COMPUTER MODEL; MOLECULAR DYNAMICS; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

ATP-BINDING CASSETTE TRANSPORTERS; COMPUTATIONAL BIOLOGY; DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 41549102797     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.12.012     Document Type: Review

References (65)

1. Pauwels E.K., et al. Multidrug resistance in cancer: its mechanism and its modulation. Drug News Perspect. 20 (2007) 371-377
2. Gottesman M.M., et al. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2 (2002) 48-58
3. Pauli-Magnus C., and Meier P.J. Hepatobiliary transporter and drug induced cholestasis. Hepatology 44 (2006) 778-787
4. Leslie E.M., et al. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204 (2005) 216-237
5. de Graaf C., et al. Cytochrome p450 in silico: an integrative modeling approach. J. Med. Chem. 48 (2005) 2725-2755
6. Thai K.-M., and Ecker G.F. Predictive models for hERG channel blockers: ligand-based and structure-based approaches. Curr. Med. Chem. 14 (2007) 3003-3026
7. Raub T.J. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol. Pharm. 1 (2006) 3-25
8. Pleban K., and Ecker G.F. Inhibitors of P-glycoprotein - lead identification and optimisation. Minirev. Med. Chem. 5 (2005) 153-163
9. Wiese M., and Pareva I.K. Structure-activity relationships of multidrug resistance reversers. Curr. Med. Chem. 8 (2001) 685-713
10. Ecker G., and Chiba P. Design and development of propafenone-type inhibitors of drug efflux pumps. Recent Res. Devel. Medicinal Chem. 1 (2001) 121-137
11. Chiba P., et al. Studies on propafenone-type modulators of multidrug resistance III: Variations on the nitrogen. Quant. Struct.-Act. Rel. 16 (1997) 361-366
12. Kaiser D., et al. Interaction field based and hologram based QSAR analysis of propafenone-type modulators of multidrug resistance. Med. Chem. 1 (2005) 431-444
13. Pajeva I.K., and Wiese M. Molecular modelling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study. J. Med. Chem. 41 (1998) 1815-1826
14. Pajeva I.K., and Wiese M. A comparative molecular field analysis of propafenone-type modulators of cancer multidrug resistance. Quant. Struct.-Act. Relat. 17 (1998) 301-312
15. Pajeava I., and Wiese M. Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety. J. Med. Chem. 45 (2002) 5671-5686
16. Garrigues A., et al. Characterization of two pharmacophores on the multidrug transporter P-glycoprotein. Mol. Pharmacol. 62 (2003) 1288-1298
17. Ekins S., et al. Three-dimensional quantitiative structure-activity relationships of inhibitors of P-glycoprotein. Mol. Pharmacol. 61 (2002) 964-973
18. Chang C., et al. Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab. Dispos. 34 (2006) 1976-1984
19. Langer T., et al. Lead identification for modulators of multidrug resistance based on in silico screening with a pharmacophoric feature model. Arch. Pharm. Pharm. Med. Chem. 337 (2004) 317-327
20. Kaiser D., et al. Self-organising maps for identification of new inhibitors of P-glycoprotein. J. Med. Chem 50 (2007) 1698-1702
21. Chiba P., and Ecker G.F. Inhibitors of ABC-type Drug Efflux Pumps - an overview on the actual patent situation. Expert Opin. Ther. Patents 14 (2004) 499-508
22. Boumendjel A., et al. Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents. Med. Res. Rev. 25 (2005) 453-472
23. Mao Q., and Unadkat J.D. Role of breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 7 (2005) E118-E133
24. van Loevezijn A., et al. Inhibiton of BCRP-mediated drug efflux by fumitremorgin-type indolyl dikeotpiperazines. Bioorg. Med. Chem. Lett. 11 (2001) 29-32
25. Cramer J., et al. Multispecificity of drug transporters: probing inhibitor selectivity for the human drug efflux transporters ABCB1 and ABCG2. Chem. Med. Chem. 2 (2007) 1783-1788
26. Xue Y. Prediction of P-glycoprotein substrates by a support vector machine approach. J. Chem. Inf. Comp. Sci. 44 (2004) 1497-1505
27. Gombar V.K., et al. P-glycoprotein substrates by a quantitative structure-activity relationship model. J. Pharm. Sci. 93 (2004) 957-968
28. Wang Y.-H., et al. Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach. J. Chem. Inf. Model. 45 (2005) 750-757
29. Huang J. Identifying P-glycoprotein substrates using a support vector machine optimized by a particle swarm. J. Chem. Inf. Model. 47 (2007) 1638-1647
30. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. 251 (1998) 252-261
31. Didziapetris R., et al. Classification analysis of P-glycoprotein substrate specificity. J. Drug Target. 11 (2003) 391-406
32. Cabrera M.A., et al. A topological substructural approach for the prediction of P-glycoprotein substrates. J. Pharm. Sci. 95 (2006) 589-606
33. De Cerqueira Lima P., et al. Combinatorial QSAR modeling of P-glycoprotein substrates. J. Chem. Inf. Model. 46 (2006) 1245-1254
34. Polli J.W., et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Therapeut. 299 (2001) 620-628
35. Quintas-Cardama A. Flying under the radar: the new wave of BCR-ABL inhibitors. Nature Rev. Drug Discov. 6 (2007) 834-848
36. http://blanco.biomol.uci.edu/Membrane_Proteins_xtal.html
37. Chang G., and Roth C.B. Roth, Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters. Science 293 (2001) 1793-1800
38. Chang G. Structure of MsbA from Vibrio cholera: a multidrug resistance ABC transporter homolog in a closed conformation. J. Mol. Biol. 330 (2003) 419-430
39. McDevitt C.A., and Callaghan R. How can we best use structural information on P-glycoprotein to design inhibitors?. Pharmacol. Ther. 113 (2007) 429-441
40. Loo T.W., et al. The 'LSGGQ' motif in each nucleotide-binding domain of human P-glycoprotein is adjacent to the opposing walker A sequence. J. Biol. Chem. 277 (2002) 41303-41306
41. Dawson R.J., and Locher K.P. Structure of a bacterial multidrug ABC transporter. Nature 443 (2006) 180-185
42. Dawson R.J., and Locher K.P. Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP. FEBS Lett. 581 (2007) 935-938
43. Locher K.P., et al. The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism. Science 296 (2002) 1091-1098
44. Pinkett H.W., et al. An inward-facing conformation of a putative metal-chelate-type ABC transporter. Science 315 (2007) 373-377
45. Hollenstein K., et al. Structure of an ABC transporter in complex with its binding protein. Nature 446 (2007) 213-216
46. Oldham M.L., et al. Crystal structure of a catalytic intermediate of the maltose transporter. Nature 450 (2007) 515-521
47. Zolnerciks J.K. Evidence for a Sav1866-like architecture for the human multidrug transporter P-glycoprotein. FASEB J. 21 (2007) 3937-3948
48. Chang G., et al. Retraction. Science 314 (2006) 1875
49. Ward A., et al. Flexibility in the ABC transporter MsbA: alternating access with a twist. PNAS 104 (2007) 19005-19010
50. O'Mara M.L., and Tielemann D.P. P-glycoprotein models of the apo and ATP-bound states based on homology with Sav1866 and MalK. FEBS Lett. 581 (2007) 4217-4222
51. Campbell J.D., et al. Extending the Structure of an ABC Transporter to Atomic Resolution: Modeling and Simulation Studies of MsbA. Biochemistry 42 (2003) 3666-3673
52. Haubertin D.Y., et al. Molecular dynamics simulations of E. coli MsbA transmembrane domain: formation of a semipore structure. Biophys. J. 91 (2006) 2517-2531
53. Vandevuer S., et al. Predicting the three-dimensional structure of human P-glycoprotein in absence of ATP by computational techniques embodying crosslinking data: insight into the mechanism of ligand migration and binding sites. Proteins 63 (2006) 466-478
54. Oloo E.O., and Tieleman D.P. Conformational transitions induced by the binding of MgATP to the vitamin B12 ATP-binding cassette (ABC) transporter BtuCD. J. Biol. Chem. 279 (2004) 45013-45019
55. Sonne J., et al. Simulation of the coupling between nucleotide binding and transmembrane domains in the ATP binding cassette transporter BtuCD. Biophys. J. 92 (2007) 2727-2734
56. Ivetac A., et al. Dynamics and function in a bacterial ABC transporter: simulation studies of the BtuCDF system and its components. Biochemistry 46 (2007) 2767-2778
57. Jones P.M., and George A.M. Mechanism of ABC transporters: a molecular dynamics simulation of a well characterized nucleotide-binding subunit. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 12639-12644
58. Campbell J.D., et al. Nucleotide-dependent conformational changes in HisP: molecular dynamics simulations of an ABC transporter nucleotide-binding domain. Biophys. J. 87 (2004) 3703-3715
59. Jones P.M., and George A.M. Nucleotide-dependent allostery within the ABC transporter ATP-binding cassette: A computational study of the MJ0796 dimer. J. Biol. Chem. 282 (2007) 22793-22803
60. Campbell, J.D. and Sansom, M.S. (2005) Nucleotide binding to the homodimeric MJ0796 protein: a computational study of a prokaryotic ABC transporter NBD dimer. FEBS Lett. 579, 4193-4199
61. Oloo E.O., et al. The dynamics of the MgATP-driven closure of MalK, the energy-transducing subunit of the maltose ABC transporter. J. Biol. Chem. 281 (2006) 28397-28407
62. Pleban K., et al. P-glycoprotein substrate binding domains are located at the transmembrane domain/transmembrane domain interface: a combined photoaffinity labeling-protein homology modelling approach. Mol. Pharmacol. 76 (2005) 365-374
63. Yu E.W. Structural basis of multiple drug-binding capacity of the AcrB multidrug efflux pump. Science 300 (2003) 976-980
64. Richter, L. et al. (2007) Ranking ligand docking poses by geometric scores: application to the GABAA receptor. Poster presentation at the 5th Joint Meeting on Medicinal Chemistry, Portoroz, June 2007
65. In silico, ADMET: the role of protein structure information in ADMET prediction. SMI Conferences, London, May 16-17, 2007